ATE471374T1 - Immunomodulatorische polynukleotide und verfahren zur deren verwendung - Google Patents

Immunomodulatorische polynukleotide und verfahren zur deren verwendung

Info

Publication number
ATE471374T1
ATE471374T1 AT01991610T AT01991610T ATE471374T1 AT E471374 T1 ATE471374 T1 AT E471374T1 AT 01991610 T AT01991610 T AT 01991610T AT 01991610 T AT01991610 T AT 01991610T AT E471374 T1 ATE471374 T1 AT E471374T1
Authority
AT
Austria
Prior art keywords
immunomodulatory polynucleotides
polynucleotides
immunomodulatory
immunomodulation
individuals
Prior art date
Application number
AT01991610T
Other languages
English (en)
Inventor
Karen Fearon
Dino Dina
Original Assignee
Dynavax Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Tech Corp filed Critical Dynavax Tech Corp
Application granted granted Critical
Publication of ATE471374T1 publication Critical patent/ATE471374T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT01991610T 2000-12-27 2001-12-27 Immunomodulatorische polynukleotide und verfahren zur deren verwendung ATE471374T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25867500P 2000-12-27 2000-12-27
PCT/US2001/050821 WO2002052002A2 (en) 2000-12-27 2001-12-27 Immunomodulatory polynucleotides and methods of using the same

Publications (1)

Publication Number Publication Date
ATE471374T1 true ATE471374T1 (de) 2010-07-15

Family

ID=22981637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01991610T ATE471374T1 (de) 2000-12-27 2001-12-27 Immunomodulatorische polynukleotide und verfahren zur deren verwendung

Country Status (12)

Country Link
US (2) US20030049266A1 (de)
EP (1) EP1364010B1 (de)
JP (1) JP4188687B2 (de)
KR (1) KR100881923B1 (de)
CN (1) CN1293192C (de)
AT (1) ATE471374T1 (de)
AU (1) AU2002231336B2 (de)
CA (1) CA2430691A1 (de)
DE (1) DE60142410D1 (de)
ES (1) ES2347525T3 (de)
NZ (1) NZ526322A (de)
WO (1) WO2002052002A2 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1999061056A2 (en) 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methods and products for inducing mucosal immunity
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
ES2421532T3 (es) * 2001-06-21 2013-09-03 Dynavax Tech Corp Compuestos inmunomoduladores quiméricos y métodos de uso de los mismos
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US20030148316A1 (en) * 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
WO2003014316A2 (en) * 2001-08-07 2003-02-20 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
AU2002361468A1 (en) * 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
JP4383534B2 (ja) * 2001-08-17 2009-12-16 コーリー ファーマシューティカル ゲーエムベーハー 改善した活性を有する組み合わせモチーフ免疫刺激オリゴヌクレオチド
WO2003054161A2 (en) * 2001-12-20 2003-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
WO2004053104A2 (en) * 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
PT1992635E (pt) 2002-12-23 2012-03-20 Dynavax Tech Corp Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos
CA2508985A1 (en) * 2002-12-23 2004-07-15 Dynavax Technologies Corporation Branched immunomodulatory compounds and methods of using the same
AU2003293196A1 (en) 2002-12-23 2004-07-29 Vical Incorporated Method for producing sterile polynucleotide based medicaments
DE602004030541D1 (de) 2003-02-20 2011-01-27 Univ Connecticut Health Ct Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
ES2569927T3 (es) * 2003-06-11 2016-05-13 Idera Pharmaceuticals, Inc. Oligonucleótidos inmunomoduladores estabilizados
WO2005011867A2 (en) 2003-07-31 2005-02-10 Handylab, Inc. Processing particle-containing samples
US8852862B2 (en) 2004-05-03 2014-10-07 Handylab, Inc. Method for processing polynucleotide-containing samples
US20060014713A1 (en) * 2004-06-15 2006-01-19 Hybridon, Inc. Immunostimulatory oligonucleotide multimers
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
CN101160401A (zh) * 2005-02-24 2008-04-09 科勒制药集团公司 免疫刺激寡核苷酸
CA2600036A1 (en) * 2005-03-04 2006-09-14 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
CA2603976A1 (en) * 2005-04-08 2006-10-19 Coley Pharmaceutical Group, Inc. Methods for treating infectious disease exacerbated asthma
US20090143761A1 (en) * 2005-06-03 2009-06-04 Transdermal Patents Company, Llc Agent delivery system and uses of same
US7998708B2 (en) 2006-03-24 2011-08-16 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US10900066B2 (en) 2006-03-24 2021-01-26 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US8883490B2 (en) 2006-03-24 2014-11-11 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
DK2001990T3 (en) 2006-03-24 2016-10-03 Handylab Inc Integrated microfluidic sample processing system and method for its use
US11806718B2 (en) 2006-03-24 2023-11-07 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
EP3222733B1 (de) 2007-07-13 2021-04-07 Handylab, Inc. Materialien zur erfassung von polynukleotiden und verfahren zu ihrer verwendung
US8182763B2 (en) 2007-07-13 2012-05-22 Handylab, Inc. Rack for sample tubes and reagent holders
US9186677B2 (en) 2007-07-13 2015-11-17 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US8287820B2 (en) 2007-07-13 2012-10-16 Handylab, Inc. Automated pipetting apparatus having a combined liquid pump and pipette head system
US8105783B2 (en) 2007-07-13 2012-01-31 Handylab, Inc. Microfluidic cartridge
EP2173912A4 (de) * 2007-08-01 2013-03-20 Idera Pharmaceuticals Inc Neuartige synthetische tlr9-agonisten
US20090047260A1 (en) * 2007-08-17 2009-02-19 Wake Forest University Health Sciences Keratin biomaterials for cell culture and methods of use
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
WO2010093882A1 (en) * 2009-02-13 2010-08-19 Wake Forest University Health Sciences Keratin biomaterials for cell culture and methods of use
AU2011258171B2 (en) 2010-05-26 2016-11-24 Selecta Biosciences, Inc. Synthetic nanocarrier combination vaccines
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
US9452212B2 (en) 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
CN106148512B (zh) 2011-04-15 2020-07-10 贝克顿·迪金森公司 扫描实时微流体热循环仪和用于同步的热循环和扫描光学检测的方法
CA2843274A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
WO2013025928A2 (en) 2011-08-17 2013-02-21 Keranetics Llc Methods for extracting keratin proteins
CA2845267C (en) 2011-08-17 2021-07-06 Keranetics Llc Low protein percentage gelling compositions
EP2773892B1 (de) 2011-11-04 2020-10-07 Handylab, Inc. Vorrichtung zur vorbereitung von polynukleotidproben
US9827245B2 (en) 2013-03-15 2017-11-28 KeraNetics, LLC Keratin compositions comprising halofuginone
US9993495B2 (en) 2015-05-29 2018-06-12 Dynavax Technologies Corporation Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung
KR20180014009A (ko) 2015-05-29 2018-02-07 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합
MX2019002925A (es) 2016-09-15 2019-09-05 Idera Pharmaceuticals Inc Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
CN109622086B (zh) * 2019-01-31 2021-10-15 河南科技大学 预置磁珠的微流控芯片、制造方法及微流控检测设备
CA3196274A1 (en) 2020-09-22 2022-03-31 Trisalus Life Sciences, Inc. Cancer therapy using toll-like receptor agonists
JP2024512765A (ja) 2021-04-01 2024-03-19 トリサルース・ライフ・サイエンシズ・インコーポレイテッド トール様受容体アゴニストを使用したがん治療
AU2022264593A1 (en) 2021-04-29 2023-11-09 Trisalus Life Sciences, Inc. Cancer therapy using checkpoint inhibitors
WO2023167868A2 (en) * 2022-03-01 2023-09-07 Icahn School Of Medicine At Mount Sinai Immunogenic compositions comprising a recombinant neuraminidase and cpg oligonucleotide adjuvant, and uses thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US552391A (en) * 1895-12-31 Concentrating-indicator for grain-elevators
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4948882A (en) * 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US5118800A (en) * 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5015733A (en) * 1983-12-20 1991-05-14 California Institute Of Technology Nucleosides possessing blocked aliphatic amino groups
US4849513A (en) * 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US5118802A (en) * 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4910300A (en) * 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
US5093232A (en) * 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US5124246A (en) * 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5460831A (en) * 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
JPH07140592A (ja) * 1993-11-16 1995-06-02 Konica Corp ハロゲン化銀写真感光材料
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69739515D1 (de) 1996-01-30 2009-09-10 Univ California Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.
US5879906A (en) * 1996-06-26 1999-03-09 Cambia Biosystems Llc Glucuronide repressors and uses thereof
ES2241042T3 (es) * 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
WO1998052962A1 (en) 1997-05-19 1998-11-26 Merck & Co., Inc. Oligonucleotide adjuvant
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
ES2283070T3 (es) * 1997-09-05 2007-10-16 The Regents Of The University Of California Utilizacion de oligonucleotidos inmunoestimulantes para la prevencion o tratamiento del asma.
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
JPH11209289A (ja) * 1998-01-22 1999-08-03 Taisho Pharmaceut Co Ltd 粘膜免疫誘起剤
EP1067956B1 (de) 1998-04-03 2007-03-14 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
AU3884199A (en) 1998-05-06 1999-11-23 Ottawa Health Research Institute Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
WO1999061056A2 (en) 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methods and products for inducing mucosal immunity
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
CA2333854A1 (en) 1998-07-27 2000-02-10 University Of Iowa Research Foundation Stereoisomers of cpg oligonucleotides and related methods
JP2003524602A (ja) 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
EP1117433A1 (de) 1998-10-09 2001-07-25 Dynavax Technologies Corporation Anti hiv zusammensetzungen, die immunstimulierende polynukleotide und hiv antigene enthalten
CA2363141C (en) 1999-02-26 2010-04-06 Chiron Corporation Microemulsions with adsorbed macromolecules and microparticles
WO2000054803A2 (en) 1999-03-16 2000-09-21 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
WO2000061151A2 (en) * 1999-04-12 2000-10-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1177439B1 (de) 1999-04-29 2004-09-08 Coley Pharmaceutical GmbH Screening nach modulatoren der funktion von immunstimulatorischer dna
WO2000067787A2 (en) 1999-05-06 2000-11-16 The Immune Response Corporation Hiv immunogenic compositions and methods
EP1204425B1 (de) 1999-08-19 2009-01-07 Dynavax Technologies Corporation Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür
IL148359A0 (en) 1999-08-27 2002-09-12 Inex Pharmaceuticals Corp Pharmaceutical compositions containing an oligodeoxynucleotide
MXPA02003108A (es) 1999-09-25 2003-10-14 Univ Iowa Res Found Acidos nucleicos inmunoestimuladores.
ATE333284T1 (de) 1999-09-27 2006-08-15 Coley Pharm Group Inc Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
WO2001051500A1 (en) 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
KR100865706B1 (ko) * 2000-09-26 2008-10-28 이데라 파마슈티칼즈, 인코포레이티드 화학적인 위치 변화에 의해 면역자극 올리고누클레오티드유사체의 면역자극 활성을 조절하는 방법
ES2421532T3 (es) * 2001-06-21 2013-09-03 Dynavax Tech Corp Compuestos inmunomoduladores quiméricos y métodos de uso de los mismos
WO2003014316A2 (en) 2001-08-07 2003-02-20 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
AU2001281267B2 (en) * 2001-08-10 2008-05-15 Dynavax Technologies Corporation Immunomodulatory oligonnucleotide formulations and methods for use thereof
AU2002361468A1 (en) 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
JP4383534B2 (ja) 2001-08-17 2009-12-16 コーリー ファーマシューティカル ゲーエムベーハー 改善した活性を有する組み合わせモチーフ免疫刺激オリゴヌクレオチド

Also Published As

Publication number Publication date
AU2002231336B2 (en) 2007-06-28
US20030049266A1 (en) 2003-03-13
EP1364010A2 (de) 2003-11-26
ES2347525T3 (es) 2010-11-02
CA2430691A1 (en) 2002-07-04
JP4188687B2 (ja) 2008-11-26
US20080207550A1 (en) 2008-08-28
EP1364010B1 (de) 2010-06-16
WO2002052002A2 (en) 2002-07-04
CN1483079A (zh) 2004-03-17
KR100881923B1 (ko) 2009-02-04
WO2002052002A3 (en) 2003-09-04
KR20030064882A (ko) 2003-08-02
DE60142410D1 (de) 2010-07-29
US8372413B2 (en) 2013-02-12
JP2004525616A (ja) 2004-08-26
NZ526322A (en) 2005-06-24
CN1293192C (zh) 2007-01-03

Similar Documents

Publication Publication Date Title
ATE471374T1 (de) Immunomodulatorische polynukleotide und verfahren zur deren verwendung
ATE544772T1 (de) Immunstimulierende sequenz-oligonukleotide und verwendungsverfahren dafür
DE60206472D1 (de) Verfahren und vorrichtung zur herstellung von mineralwolle
DE60226484D1 (de) System und verfahren zur zuverlässigkeitsbewertung
DE60217597D1 (de) Gerät und Verfahren zur Personenerkennung
DE60207175D1 (de) System und Verfahren zur Authentifizierung
DE50010130D1 (de) Verfahren zur herstellung von im-ohr-hörgeräten und im-ohr-hörgerät
DE60226674D1 (de) Verfahren und Vorrichtung zur Ausrüstung von Bohrlöchern
DE60106854D1 (de) Verfahren und Vorrichtung zur Elektroentionisierung von Wasser
DE60207863D1 (de) Vorrichtung und Verfahren zur Gesichtserkennung
DE60220494D1 (de) Verfahren zur Iriserkennung und System unter Verwendung desselben
DE69916255D1 (de) System und verfahren zur geräuschkompensierten spracherkennung
ATE299060T1 (de) Verfahren und vorrichtung zur drehbearbeitung
DE60226783D1 (de) Mikrofluidische Vorrichtung, Verfahren zur Herstellung und Verwendung desselben
DE69901178D1 (de) Nichtgesinterte elektrode und verfahren zur herstellung
AT4947U3 (de) Vollnarbiges rindnappaleder und verfahren zur herstellung desselben
DE10107712B4 (de) Vorrichtung und Verfahren zur energetischen Nutzung von Faulschlammvergasungsgas
DE60235170D1 (de) Detektionsverfahren und verfahren zur quantitativen analyse von wasserstoffradikalen
DE60333304D1 (de) Gleitteil und verfahren zur herstellung des gleitteils
DE50111926D1 (de) Strahlungsanordnung sowie deren Verwendung und Verfahren zur Behandlung von Oberflächen
DE60221018D1 (de) Verfahren und vorrichtung zur herstellung von kontaktlinsen
DE60315575D1 (de) Verfahren und Vorrichtung zur Untersuchung von Oberflächen
DE60221175D1 (de) Verfahren und Vorrichtung zur Herstellung von plattenförmigen metallischen Materialien
DE60210184D1 (de) L-cystein herstellendes Bakterium und Verfahren zur Herstellung von L-cystein
DE60104022D1 (de) System und verfahren zur spannungsschaltung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties